Neoadjuvant Study of Two Platinum Regimens in Triple Negative Breast Cancer (NeoSTOP)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02413320 |
Recruitment Status :
Completed
First Posted : April 9, 2015
Results First Posted : April 30, 2021
Last Update Posted : May 10, 2021
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Triple-negative Breast Cancer | Drug: Paclitaxel Drug: Carboplatin Drug: Doxorubicin Drug: Cyclophosphamide Drug: Docetaxel | Phase 2 |
Sporadic and germline BRCA mutation associated triple-negative breast cancer share several pathological and molecular similarities which have led to the exploration of DNA damaging agents like platinum compounds in patients with triple-negative breast cancer. Recent studies demonstrate that addition of neoadjuvant carboplatin to doxorubicin/cyclophosphamide/taxane-based chemotherapy improves pathological complete response in patients with stage I-III triple-negative breast cancer but also increase toxicity.
A recent study reported encouraging pathological complete response rates with a non-anthracycline carboplatin plus docetaxel neoadjuvant chemotherapy regimen in a cohort of 49 triple negative breast cancer patients. This chemotherapy regimen of carboplatin plus docetaxel yielded an overall pathological complete response rate of 65% in unselected triple-negative breast cancer with pathological complete response rates of 61% in sporadic and 77% in germline BRCA-associated triple-negative breast cancer. The chemotherapy regimen of carboplatin/docetaxel is well tolerated and should be studied further and compared with regimens that add carboplatin to the standard anthracycline/taxane containing regimens.
This is the basis for the proposed randomized neoadjuvant phase II study to further estimate and compare pathological complete response rates of carboplatin plus docetaxel x 6 cycles to carboplatin plus paclitaxel x 4 cycles followed by doxorubicin plus cyclophosphamide x 4 cycles in stage I-III triple negative-breast cancer.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 101 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Randomized Open Label Phase II Trial of Neoadjuvant Carboplatin Plus Docetaxel or Carboplatin Plus Paclitaxel Followed by Doxorubicin Plus Cyclophosphamide in Stage I-III Triple-negative Breast Cancer |
Study Start Date : | July 2015 |
Actual Primary Completion Date : | February 1, 2019 |
Actual Study Completion Date : | February 1, 2020 |

Arm | Intervention/treatment |
---|---|
Active Comparator: Carboplatin + Paclitaxel then Doxorubicin + Cyclophosphamide
Paclitaxel (80mg/m2) given IV every week x12 weeks and Carboplatin (AUC 6) given IV every 21 days x 4 cycles, followed by Doxorubicin (60mg/m2) given IV and Cyclophosphamide (600mg/m2) given IV every 14 days X 4 cycles
|
Drug: Paclitaxel
Other Name: taxol Drug: Carboplatin Other Name: paraplatin Drug: Doxorubicin Other Name: adriamycin Drug: Cyclophosphamide Other Name: cytoxin, procytox |
Active Comparator: Carboplatin + Docetaxel
Carboplatin (AUC 6) given IV and Docetaxel (75mg/m2) given IV every 21 days x 6 cycles
|
Drug: Carboplatin
Other Name: paraplatin Drug: Docetaxel Other Name: taxotere |
- Number of Participants With Pathological Complete Response [ Time Frame: 20 weeks ]To evaluate the pathological complete response rates with neoadjuvant chemotherapy regimens of carboplatin plus paclitaxel x 4 cycles followed by doxorubicin plus cyclophosphamide X 4 cycles and carboplatin plus docetaxel X 6 cycles in subjects with stage I-III triple-negative breast cancer. Pathological complete response is defined as no evidence of disease in the breast and axilla at the time of pathology review except for DCIS.
- Number of Participants With Minimal Residual Disease [ Time Frame: 20 weeks ]To evaluate minimal residual disease rates (residual cancer burden 0+1) with two neoadjuvant chemotherapy regimens in subjects with stage I-III triple-negative breast cancer.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 70 Years (Adult, Older Adult) |
Sexes Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patients with newly diagnosed stage I (T>1cm), II or III triple negative breast cancer who have not had definitive breast surgery or received systemic chemotherapy
- The invasive tumor must be hormone receptor-poor, defined as both estrogen receptor and progesterone receptor staining present in ≤ 10% of invasive cancer cells by Immunohistochemistry.
- HER- 2 negativity will be based on the current ASCO-CAP guidelines for HER testing
- No prior chemotherapy, endocrine therapy or radiation therapy with therapeutic intent for this cancer
- Female subjects age 18 - 70 years
- ECOG Performance Status of 0-1
-
Adequate organ and marrow function as defined below:
- Leukocytes ≥ 3,000/uL
- Absolute neutrophil count ≥ 1500/uL
- Platelets ≥ 100,000/uL
- Total bilirubin ≤ 1.5mg/dL
- AST(SGOT)/ALT(SPGT) ≤ 2 x institutional upper limit of normal
- Creatinine ≤ 1.5mg/dl and/or Creatinine Clearance ≥ 60mL/min
- Serum albumin ≥ 3.0 g/dL
- Women of child-bearing potential must agree to use adequate contraception
- Pretreatment lab values must be performed within 14 days of treatment initiation, and other baseline studies performed within 30 days prior to registration
- Subjects should have LVEF ≥ 50% by echocardiogram or MUGA scan performed within 4 weeks prior to treatment initiation
- Subjects should have breast and axillary imaging with breast MRI or breast and axillary ultrasound within 4 weeks prior to treatment initiation
- Subjects with clinically/radiologically abnormal axillary lymph nodes should have pathological confirmation of disease with image guided biopsy/fine needle aspiration.
- Subjects must be already enrolled in P.R.O.G.E.C.T observational registry
- Staging to rule out metastatic disease is recommended for subjects with clinical stage III disease
- Subjects with bilateral disease are eligible if they meet other eligibility criteria.
- Neuropathy: No baseline neuropathy grade > 2
Exclusion Criteria:
- Current or anticipated use of other investigational agents
- Subject has received chemotherapy, radiotherapy or surgery for the treatment of breast cancer
- Subject with metastatic disease
- History of allergic reactions to compounds of similar chemical or biologic composition to carboplatin, docetaxel, doxorubicin, cyclophosphamide, paclitaxel, or other agents used in the study
- Subjects with inflammatory breast cancer
- Uncontrolled intercurrent illness including, but not limited to ongoing or active infection or psychiatric illness/social situations that would limit compliance with study requirements
- Subject is pregnant or nursing
- Subjects with concomitant or previous malignancies within the last 5 years. Exceptions include: adequately treated basal or squamous cell carcinoma of the skin, carcinoma in situ of the cervix, and ductal carcinoma in situ (DCIS).
- Ejection Fraction <50% on ECHO or MUGA
- Cardiac function: Subjects with congestive heart failure, myocardial infarction, unstable angina pectoris, an arterial thrombotic event, stroke or transient ischemia attack within the past 12 months, uncontrolled hypertension (Systolic BP>160 or Diastolic BP>90), uncontrolled or symptomatic arrhythmia, or grade ≥ 2 peripheral vascular disease

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02413320
United States, Kansas | |
University of Kansas Cancer Center - CRC | |
Fairway, Kansas, United States, 66205 | |
Hays Medical Center | |
Hays, Kansas, United States, 67601 | |
University of Kansas Cancer Center - Overland Park | |
Overland Park, Kansas, United States, 66210 | |
Salina Regional Health Center | |
Salina, Kansas, United States, 67401 | |
University of Kansas Cancer Center - Westwood | |
Westwood, Kansas, United States, 66205 | |
United States, Missouri | |
Truman Medical Center | |
Kansas City, Missouri, United States, 64108 | |
University of Kansas Cancer Center - South | |
Kansas City, Missouri, United States, 64131 | |
University of Kansas Cancer Center - North | |
Kansas City, Missouri, United States, 64154 | |
University of Kansas Cancer Center - Lee's Summit | |
Lee's Summit, Missouri, United States, 64064 |
Principal Investigator: | Priyanka Sharma, MD | University of Kansas Medical Center |
Documents provided by Priyanka Sharma, University of Kansas Medical Center:
Responsible Party: | Priyanka Sharma, Medical Doctor, University of Kansas Medical Center |
ClinicalTrials.gov Identifier: | NCT02413320 |
Other Study ID Numbers: |
2015-IIT-Neoadjuvant-BRST-TNBC |
First Posted: | April 9, 2015 Key Record Dates |
Results First Posted: | April 30, 2021 |
Last Update Posted: | May 10, 2021 |
Last Verified: | May 2021 |
TNBC, breast cancer, neoadjuvant, carboplatin, docetaxel, paclitaxel, doxorubicin, cyclophosphamide |
Breast Neoplasms Triple Negative Breast Neoplasms Neoplasms by Site Neoplasms Breast Diseases Skin Diseases Paclitaxel Docetaxel Cyclophosphamide Carboplatin Doxorubicin Antineoplastic Agents, Phytogenic Antineoplastic Agents Tubulin Modulators |
Antimitotic Agents Mitosis Modulators Molecular Mechanisms of Pharmacological Action Immunosuppressive Agents Immunologic Factors Physiological Effects of Drugs Antirheumatic Agents Antineoplastic Agents, Alkylating Alkylating Agents Myeloablative Agonists Antibiotics, Antineoplastic Topoisomerase II Inhibitors Topoisomerase Inhibitors Enzyme Inhibitors |